Current Issue's

Feature Articles

Apr - May 2019

Yoga for Chronic Disease Management

In today's western society, the word "yoga" often invokes images of young and fit participants dressed in vibrantly colored stretchy yoga pants and posed in seemingly unattainable postures. While many consider yoga a textbook example of cultural appropriation, that doesn't mean everyone shouldn't be able to benefit from this ancient practice... full article

Preparing for College with a Chronic Illness

Graduating high school can be one of the most exciting and scary times in young adults' lives. For most, completing secondary education represents having achieved their first milestone on the road to success as an adult. And, while this triumph culminates years of hard study for all students, it is a particularly impressive accomplishment for graduates who are battling chronic illness... full article

Properly Disposing of Medicines

According to research, most people understand the importance of disposing of unneeded and/or expired medicines, yet one in five reports being unaware of safe disposal guidelines.1 Failure to heed the advice of health and government organizations on how to safely dispose of medicines can be dangerous for a variety of reasons. For starters, medications lose their effectiveness after the expiration date, and some may be toxic.... full article

The 'Right to Try' Law: What Does It Mean for Patients?

On May 30, 2018, President Trump signed into law SB 204, the "right to try" law allowing terminally ill patients the legal right to request access to experimental drugs not yet approved by the U.S. Food and Drug Administration (FDA). While much discourse has been made by activists on both sides of the political debate surrounding the new law, the few neutral analyses indicate the law is more of a symbolic victory for "right-to-try" advocates that will likely have relatively small practical ramifications for patients and their families... full article

Managing and Treating ITP

Once known as idiopathic thrombocytopenic purpura (ITP), the name for this rare condition has evolved over time as understanding about its mechanisms has advanced. ITP was first described almost a thousand years. But, it wasn't until 1915 that controversy arose regarding the mechanism of ITP. It was then that German physician Ernest Frank suggested ITP was caused by suppression of megakaryocytes (cells present in bone marrow) by a substance produced in the spleen, whereas Czech scientist Paul Kaznelson suggested it was caused due to increased destruction of platelets in the spleen... full article